Items where authors include "Helliwell, P"
Up a levelArticle
Chapman, LS, Redmond, AC, Flurey, CA et al. (14 more authors) (2023) Developing an Outcome Measures in Rheumatology (OMERACT) Core set of Outcome Measures for FOot and ankle disorders in RheumaTic and musculoskeletal diseases (COMFORT): core domain set study protocol. Trials, 24. 65. ISSN 1745-6215
Coates, LC, Soriano, ER, Corp, N et al. (42 more authors) (2022) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nature Reviews Rheumatology, 18 (8). pp. 465-479. ISSN 1759-4790
Coates, LC, Garrood, T, Gullick, N et al. (8 more authors) (2022) Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC. Rheumatology. ISSN 1462-0324
Chapman, LS, Backhouse, M orcid.org/0000-0003-0056-8467, Bearne, L et al. (19 more authors) (2022) Management of foot health in people with inflammatory arthritis: British Society for Rheumatology guideline scope. Rheumatology. ISSN 1462-0324
Macleod, T, Bridgewood, C, Hyde, I et al. (4 more authors) (2022) Molecular and cellular regulation of psoriatic inflammation. Clinical Science, 136 (12). pp. 935-952. ISSN 0143-5221
Tucker, L, Allen, A, Chandler, D et al. (16 more authors) (2022) The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. Rheumatology. ISSN 1462-0324
Tucker, L, Allen, A, Chandler, D et al. (16 more authors) (2022) Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. Rheumatology. keac260. ISSN 1462-0324
Dubash, S, Alabas, OA, Michelena, X et al. (7 more authors) (2021) Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naive early psoriatic arthritis. Annals of the Rheumatic Diseases. ISSN 0003-4967
Tillett, W, Allen, A, Tucker, L et al. (17 more authors) (2020) Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope. Rheumatology. keaa526. ISSN 1462-0324
Ritchlin, CT, Giles, JT, Ogdie, A et al. (8 more authors) (2020) Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies. ACR Open Rheumatology, 2 (10). pp. 543-554. ISSN 2578-5745
Walker, D, Robinson, S, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (1 more author) (2020) Development and validation of a bi-lingual interactive tool to educate people about osteomalacia. Musculoskeletal Care, 18 (3). pp. 265-270. ISSN 1478-2189
Tillett, W and Helliwell, P (2020) To Lump or Split When Assessing Psoriatic Arthritis — Not Mutually Exclusive? The Journal of Rheumatology, 47 (3). pp. 307-309. ISSN 0315-162X
Jadon, DR, Chandran, V, Ogdie, A et al. (12 more authors) (2019) Proceedings of the 2018 GRAPPA Collaborative Research Network Meeting. The Journal of Rheumatology Supplement, 95. pp. 11-19. ISSN 0380-0903
McGonagle, D, Tan, AL, Watad, A et al. (1 more author) (2019) Pathophysiology, assessment and treatment of psoriatic dactylitis. Nature Reviews Rheumatology, 15 (2). pp. 113-122. ISSN 1759-4790
Helliwell, P, Coates, LC, FitzGerald, O et al. (8 more authors) (2018) Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. Arthritis Research and Therapy, 20. 242. ISSN 1478-6354
Berekméri, A, Latzko, A, Alase, A et al. (12 more authors) (2018) Detection of IL-36γ through noninvasive tape stripping reliably discriminates psoriasis from atopic eczema. Journal of Allergy and Clinical Immunology, 142 (3). 988-991.e4. ISSN 0091-6749
Berekmeri, A, Mahmood, F, Wittmann, M orcid.org/0000-0003-2328-4926 et al. (1 more author) (2018) Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert review of clinical immunology, 14 (9). pp. 719-730. ISSN 1744-666X
Packham, JC, Abraham, S, Kirkham, B et al. (8 more authors) (2018) A new era for collaboration? Rheumatology, 57 (5). pp. 775-776. ISSN 1462-0324
Højgaard, P, Klokker, L, Orbai, A-M et al. (17 more authors) (2018) A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. Seminars in Arthritis and Rheumatism, 47 (5). pp. 654-665. ISSN 0049-0172
Smolen, JS, Schöls, M, Braun, J et al. (34 more authors) (2018) Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Annals of the Rheumatic Diseases, 77 (1). pp. 3-17. ISSN 0003-4967
Patton, T, Bojke, L, Walton, M et al. (2 more authors) (2017) Evaluating the cost-effectiveness of biologic treatments for psoriatic arthritis: can we make better use of patient data registries? Clinical Rheumatology, 36 (8). pp. 1803-1810. ISSN 0770-3198
De Marco, G, Helliwell, P, McGonagle, D et al. (4 more authors) (2017) The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes. BMC Musculoskeletal Disorders, 18. 303. ISSN 1471-2474
Waxman, R, Adebajo, A, Robinson, S et al. (7 more authors) (2017) A feasibility study of educational tools for osteomalacia. Clinical Rheumatology, 36 (3). pp. 635-640. ISSN 0770-3198
Rothery, C, Bojke, L, Richardson, G et al. (6 more authors) (2016) A discrete choice experiment to explore patients’ willingness to risk disease relapse from treatment withdrawal in psoriatic arthritis. Clinical Rheumatology, 35 (12). pp. 2967-2974. ISSN 0770-3198
Murphy, SM, Lilleker, JB, Helliwell, P et al. (1 more author) (2016) The successful use of tocilizumab as third-line biologic therapy in a case of refractory anti-synthetase syndrome. Rheumatology, 55 (12). pp. 2277-2278. ISSN 1462-0324
Coates, L and Helliwell, P (2016) More than meets the eye? The Lancet, 388 (10060). e15-e15. ISSN 0140-6736
Gudu, T, Etcheto, A, de Wit, M et al. (16 more authors) (2016) Fatigue in psoriatic arthritis - a cross-sectional study of 246 patients from 13 countries. Joint Bone Spine, 83 (4). pp. 439-443. ISSN 1778-7254
Kavanaugh, A, Helliwell, P and Ritchlin, CT (2016) Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. Rheumatology and Therapy, 3 (1). pp. 91-102. ISSN 2198-6576
De Lautour, H, Taylor, WJ, Adebajo, A et al. (36 more authors) (2016) Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. Arthritis Care and Research, 68 (5). pp. 667-672. ISSN 2151-464X
Tälli, S, Etcheto, A, Fautrel, B et al. (18 more authors) (2016) Patient global assessment in psoriatic arthritis – what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study. Joint Bone Spine, 83 (3). pp. 335-340. ISSN 1297-319X
Gossec, L, Smolen, JS, Ramiro, S et al. (31 more authors) (2016) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Annals of the Rheumatic Diseases, 75 (3). pp. 499-510. ISSN 0003-4967
Coates, LC and Helliwell, P (2016) Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study. Journal of Rheumatology, 43 (2). pp. 356-361. ISSN 0315-162X
Bowes, J, Loehr, S, Budu-Aggrey, A et al. (21 more authors) (2015) PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. Annals of the Rheumatic Diseases, 74 (10). pp. 1882-1885. ISSN 0003-4967
Bowes, J, Budu-Aggrey, A, Huffmeier, U et al. (29 more authors) (2015) Corrigendum: Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. Nature Communications, 6. 7741.
Bowes, J, Budu-Aggrey, A, Huffmeier, U et al. (29 more authors) (2015) Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. Nature Communications, 6. 6046. ISSN 2041-1723
Wilkins, R, Siddle, H orcid.org/0000-0002-6015-332X, Redmond, A et al. (1 more author) (2014) Exploratory study to identify mechanical factors that may contribute to toe dactylitis in patients with psoriatic arthritis. Journal of Foot and Ankle Research, 7 (S2). A8.
Firth, J, Waxman, R, Law, G et al. (12 more authors) (2014) The predictors of foot ulceration in patients with rheumatoid arthritis. Clinical Rheumatology, 33 (5). 615 - 621. ISSN 0770-3198
Gossec, L, Smolen, JS, Gaujoux-Viala, C et al. (32 more authors) (2012) European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Annals of the Rheumatic Diseases, 71 (1). pp. 4-12. ISSN 0003-4967
Conference or Workshop Item
Mease, P, Helliwell, P orcid.org/0000-0002-4155-9105, Gladman, D et al. (10 more authors) (2022) Effect of Guselkumab a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients With Active PsA: Results From a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years. In: Canadian Rheumatology Association Annual Meeting, 02-05 Feb 2022, Online.
Rahman, P, Ritchlin, C, Mease, P et al. (10 more authors) (2022) Long-term Safety of Guselkumab in Patients With Active Psoriatic Arthritis: Pooled Results From 3 Randomized Clinical Trials Through Up to 2 Years. In: Open Access Canadian Rheumatology Association Annual Meeting, 02-05 Feb 2022, Online.
Tillett, W, Day, J, Mchugh, N et al. (3 more authors) (2021) Continuous Composite Measures for Routine Care in Psoriatic Arthritis: Thresholds of Meaning and Clinically Important Difference Estimates for the 3 and 4 VAS Scales from a UK Multicentre Study. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.
Mease, PJ, Coates, LC, Van den Bosch, F et al. (8 more authors) (2021) Correlation Between Skin Involvement, Joint Involvement and Enthesitis in Patients with Active Psoriatic Arthritis: Post-hoc Analysis of EQUATOR/EQUATOR2. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.
Kavanaugh, A, Liu, Y, Deodhar, A et al. (8 more authors) (2021) Correlations Between Reductions in Fatigue Severity and Improvements in Physical Function and Clinical Response in Patients with Psoriatic Arthritis: Results from the Phase 3 Discover Program. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.
Helliwell, P orcid.org/0000-0002-4155-9105, Coates, LC, Van den Bosch, F et al. (7 more authors) (2021) The Effect of Filgotinib on Enthesitis: 100-Week Data from an Open-Label Extension Study in Patients with Active Psoriatic Arthritis. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.
Coates, LC, Mease, PJ, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (8 more authors) (2021) Effect of Filgotinib on Pasdas: Drivers of Low and Very Low Activity up to Week 100. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.
Behrens, F, Mease, PJ, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (8 more authors) (2021) Efficacy of Guselkumab Across Basdai Components in Treating Axial-Related Symptoms of Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-Controlled Studies. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.
Orbai, AM, Mease, PJ, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (5 more authors) (2021) Efficacy of Tofacitinib on Dactylitis in Individual Digits in Patients with Active Psoriatic Arthritis. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.
Coates, LC, Soriano, E, Corp, N et al. (31 more authors) (2021) The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Treatment Recommendations 2021. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.
Coates, LC, Ritchlin, CT, Gossec, L et al. (12 more authors) (2021) Guselkumab Provides Sustained Domain-Specific and Comprehensive Efficacy as Assessed using Composite Endpoints in Patients with Active Psoriatic Arthritis. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.
Orbai, AM, Coates, LC, Deodhar, A et al. (9 more authors) (2021) Guselkumab-Treated Patients with Psoriatic Arthritis Achieved Clinically Meaningful Improvements in General Health Outcomes Measured with PROMIS-29 Through 52 Weeks: Results from the Phase 3 Discover-1 Trial. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.
Rahman, P, Helliwell, P orcid.org/0000-0002-4155-9105, Deodhar, A et al. (6 more authors) (2021) In Phase-3 Trials Discover 1 & 2, Guselkumab Reduced Fatigue over 52 Weeks in Patients with Psoriatic Arthritis and Demonstrated Independent Treatment Effects on Fatigue after Adjustment for Clinical Response (ACR20). In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.
Mease, PJ, Foley, P, Reich, K et al. (14 more authors) (2021) Low Incidence of Gastrointestinal-Related and Overall Serious Adverse Events among Guselkumab-Treated Patients: Pooled Analyses of Voyage 1 & 2 and Discover 1 & 2 Through 1-Year. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.
Ritchlin, CT, Rahman, P, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (13 more authors) (2021) Pooled Safety Results from Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis through 1 Year. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.
Dubash, S, Alabas, OA, Michelena, X et al. (7 more authors) (2021) Dactylitis is associated with greater disease severity, CRP, ultrasound determined synovitis, and erosive damage in DMARD-naïve early PsA. In: British Society for Rheumatology Annual Conference 2021, 26-28 Apr 2021, Virtual.
Coates, LC, Garrood, T, Gullick, N et al. (8 more authors) (2021) Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC. In: British Society for Rheumatology Annual Conference 2021, 26-28 Apr 2021, Virtual.
Tucker, L, Helliwell, P orcid.org/0000-0002-4155-9105, Coates, L et al. (1 more author) (2021) Which composite measure best reflects disease activity and predicts treatment change in psoriatic arthritis? In: British Society for Rheumatology Annual Conference 2021, 26-28 Apr 2021, Virtual.
Mease, P, Helliwell, P orcid.org/0000-0002-4155-9105, Gladman, D et al. (12 more authors) (2021) Efficacy of Guselkumab on Axial-Related Endpoints in Patients with Active Psoriatic Arthritis with Imaging-Confirmed Sacroiliitis. In: Twelfth International Congress on Spondyloarthritides, 09-11 Sep 2021, Virtual.
Rahman, P, Ritchlin, C, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (12 more authors) (2021) Integrated Safety Results of Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis through the Placebo-Controlled Periods. In: Twelfth International Congress on Spondyloarthritides, 09-11 Sep 2021, Virtual.
Kavanaugh, A, Helliwell, P orcid.org/0000-0002-4155-9105, Sesin, C et al. (6 more authors) (2021) Low Disease Thresholds up to Three Years in Ixekizumab-Treated Patients with Psoriatic Arthritis in SPIRIT-P1 and SPIRIT-P2. In: Twelfth International Congress on Spondyloarthritides, 09-11 Sep 2021, Virtual.
Mease, P, Coates, L, Van den Bosch, F et al. (7 more authors) (2020) Effect of Filgotinib on the Complete Resolution of Enthesitis in Psoriatic Arthritis (PsA) Patients: 52-week Results from EQUATOR2. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.
Mease, P, Helliwell, P orcid.org/0000-0002-4155-9105, Gladman, D et al. (15 more authors) (2020) Efficacy of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19 Subunit of IL-23, on Axial-Related Endpoints in Patients with Active PsA with Imaging-Confirmed Sacroiliitis: Week-52 Results from Two Phase 3, Randomized, Double-blind, Placebo-controlled Studies. In: 37º Congresso Brasileiro de Reumatologia, 19-22 Nov 2020, Virtual.
Orbai, A-M, Mease, P, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (5 more authors) (2020) Efficacy of Tofacitinib on Dactylitis in Individual Digits in Patients with Active Psoriatic Arthritis. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.
Ritchlin, C, Deodhar, A, Boehncke, W-H et al. (10 more authors) (2020) Guselkumab Efficacy and Safety in TNF-Inhibitor-Experienced and TNF-Inhibitor-Naive Patients with Active PsA: 1-Year Results of a Phase 3, Randomized, Controlled Study. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.
Coates, L, Ritchlin, C, Gossec, L et al. (12 more authors) (2020) Guselkumab Provides Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis. In: ACR Convergence 2020, 05-09 Nov 2021, Virtual.
Ritchlin, C, Helliwell, P orcid.org/0000-0002-4155-9105, Boehncke, W-H et al. (8 more authors) (2020) Guselkumab, an IL-23 Inhibitor That Specifically Binds to the IL23p19-Subunit, for Active Psoriatic Arthritis: One Year Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Patients Who Were Biologic-Naïve or TNFα Inhibitor-Experienced. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.
Orbai, A-M, Coates, L, Deodhar, A et al. (8 more authors) (2020) Guselkumab-Treated Patients Achieved Clinically Meaningful Improvement in Systemic Symptoms as Measured with PROMIS Instrument: Results from Phase-3 Psoriatic Arthritis Trial DISCOVER 1. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.
Coates, L, Gladman, D, Van den Bosch, F et al. (10 more authors) (2020) Long-term Outcomes with Filgotinib, an Oral Selective Janus Kinase 1 Inhibitor: 100-week Data from an Open-label Extension (OLE) Study in Patients with Active Psoriatic Arthritis (PsA). In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.
Helliwell, P orcid.org/0000-0002-4155-9105, Mease, P, Kavanaugh, A et al. (9 more authors) (2020) What Influence Do Clinical Domains Other Than Arthritis Have on Composite Clinical Outcomes in Psoriatic Arthritis?: Comparison of Treatment Effects in the SEAM-PsA Trial. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.
Coates, L, Mease, P, Gladman, D et al. (8 more authors) (2020) Long-Term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study. In: British Society for Rheumatology Annual Conference 2020, 20-22 Apr 2020.
Dubash, S, Alabas, O, Michelena, X et al. (9 more authors) (2020) SAT0401 Swollen joints are associated with ultrasound power Doppler synovitis, whereas tender joints in the absence of swelling are not: an analysis of agreement and correlation in very early DMAR naïve Psoriatic arthritis. In: European League Against Rheumatism (EULAR) 2020, 03-06 Jun 2020, Online.
Orbai, AM, Coates, LC, Deodhar, A et al. (8 more authors) (2020) AB0813 GUSELKUMAB-TREATED PATIENTS ACHIEVED CLINICALLY MEANINGFUL IMPROVEMENT IN SYSTEMIC SYMPTOMS AS MEASURED WITH PROMIS INSTRUMENT: RESULTS FROM PHASE-3 PSORIATIC ARTHRITIS TRIAL DISCOVER 1. In: EULAR 2020, 03-06 Jun 2020, Online.
Poddubnyy, D, Mease, PJ, Van den Bosch, F et al. (9 more authors) (2020) AB0824 WHICH PARAMETERS ARE RELEVANT IN THE IDENTIFYING AXIAL INVOLVEMENT IN PSORIATIC ARTHRITIS? – RESULTS OF A SURVEY AMONG ASAS AND GRAPPA MEMBERS. In: EULAR 2020, 03-06 Jun 2020, Online.
Ritchlin, CT, Ogdie, A, Giles, JT et al. (9 more authors) (2020) AB0827 IMPACT OF BASELINE BODY MASS INDEX ON THE EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS. In: EULAR 2020, 03-06 Jun 2020, Online.
Tillett, W, Helliwell, P, Fitzgerald, O et al. (13 more authors) (2020) AB0839 RELIABILITY OF COMPOSITE MEASURES FOR THE ASSESSMENT OF PSORIATIC ARTHRITIS. In: EULAR 2020, 03-06 Jun 2020, Online.
Helliwell, P, Tillett, W, Waxman, R et al. (4 more authors) (2020) AB1241 EVALUATION OF A PATIENT COMPLETED DISEASE FLARE QUESTIONNAIRE IN PSORIATIC DISEASE. In: EULAR 2020, 03-06 Jun 2020, Online.
Gladman, DD, Coates, LC, Van den Bosch, F et al. (9 more authors) (2020) FRI0339 LONG-TERM EFFICACY OF THE ORAL SELECTIVE JANUS KINASE 1 INHIBITOR FILGOTINIB IN PSORIATIC ARTHRITIS: WEEK 52 RESPONSE PATTERNS IN INDIVIDUAL PATIENTS FROM AN OPEN-LABEL EXTENSION (OLE) STUDY (EQUATOR2). In: EULAR 2020, 03-06 Jun 2020, Online.
Helliwell, P, Van den Bosch, F, Coates, LC et al. (9 more authors) (2020) FRI0343 EFFICACY AND SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: SUBGROUP ANALYSES FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL (EQUATOR). In: EULAR 2020, 03-06 Jun 2020, Online.
Husni, ME, Gladman, DD, Helliwell, P et al. (9 more authors) (2020) FRI0344 THE LONG-TERM EFFECT OF TREATING PSORIATIC ARTHRITIS WITH THE JANUS KINASE 1-SELECTIVE INHIBITOR FILGOTINIB ON LIPID PROFILES: AN ANALYSIS OF THE EQUATOR AND EQUATOR2 TRIALS. In: EULAR 2020, 03-06 Jun 2020, Online.
Rahman, P, Ritchlin, CT, Helliwell, P et al. (13 more authors) (2020) FRI0359 INTEGRATED SAFETY RESULTS OF TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH THE PLACEBO-CONTROLLED PERIODS. In: EULAR 2020, 03-06 Jun 2020, Online.
Helliwell, P, Gladman, DD, Poddubnyy, D et al. (13 more authors) (2020) OP0054 EFFICACY OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF IL-23, ON ENDPOINTS RELATED TO AXIAL INVOLVEMENT IN PATIENTS WITH ACTIVE PSA WITH IMAGING-CONFIRMED SACROILIITIS: WEEK-24 RESULTS FROM TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES. In: EULAR 2020, 03-06 Jun 2020, Online.
Ritchlin, CT, Helliwell, P, Boehncke, WH et al. (8 more authors) (2020) SAT0397 GUSELKUMAB, AN IL-23 INHIBITOR THAT SPECIFICALLY BINDS TO THE IL23P19-SUBUNIT, FOR ACTIVE PSORIATIC ARTHRITIS: ONE YEAR RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PATIENTS WHO WERE BIOLOGIC-NAÏVE OR TNFΑ INHIBITOR-EXPERIENCED. In: EULAR 2020, 03-06 Jun 2020, Online.
Dubash, S orcid.org/0000-0002-9303-7122, Alabas, O, Michelena, X et al. (8 more authors) (2020) SAT0413 Dactylitis is associated with disease severity and ultrasound defined erosive damage in very early, DMARD naïve Psoriatic arthritis. In: European League Against Rheumatism (EULAR) 2020, 03-06 Jun 2020, Online.
Helliwell, P, Rahman, P, Deodhar, A et al. (6 more authors) (2020) SAT0421 GUSELKUMAB DEMONSTRATED AN INDEPENDENT TREATMENT EFFECT ON FATIGUE AFTER ADJUSTMENT FOR CLINICAL RESPONSE (ACR20) IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM PHASE-3 TRIALS DISCOVER 1 & 2. In: EULAR 2020, 03-06 Jun 2020, Online.
Ogdie, A, Weinstein, S, Coates, LC et al. (2 more authors) (2020) SAT0433 TRIAL SIMULATION TO INFORM ENROLLMENT CRITERIA AND OUTCOME MEASURES FOR PRAGMATIC TRIALS IN PsA. In: EULAR 2020, 03-06 Jun 2020, Online.
Deodhar, A, Helliwell, P, Boencke, W-H et al. (8 more authors) (2020) GUSELKUMAB, AN ANTI-INTERLEUKIN-23P19-SUBUNIT MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO WERE BIOLOGIC-NAIVE OR PRIOR TNF alpha INHIBITOR-TREATED: WEEK 24 RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. In: 22nd PANLAR Congress, 12-15 Aug 2020, Miami, Florida, USA.
Coates, L, Mease, P, Gladman, D et al. (8 more authors) (2020) Long-term safety of filgotinib in patients with PsA: week 52 safety data from a Phase 2 open-label extension study. In: British Society for Rheumatology Annual Conference 2020, 20-22 Apr 2020, Cancelled.
Deodhar, A, Helliwell, P, Boehncke, W-H et al. (8 more authors) (2020) P262 Guselkumab, an anti-interleukin-23p19 monoclonal antibody, in patients with active PsA who were biologic-naïve or prior TNFα inhibitor-treated: week 24 results of a Phase 3, randomised, double-blind, placebo-controlled study. In: British Society for Rheumatology Annual Conference, 20-22 Apr 2020, Online.
Deodhar, A, Kirkham, B, Rahman, P et al. (6 more authors) (2020) P277 Assessment of disease activity using RAPID3 and evaluation of treatment effect of guselkumab in patients with PsA: results from a randomised placebo-controlled Phase 2 clinical trial. In: British Society for Rheumatology Annual Conference 2020, 20-22 Apr 2020, Cancelled.
Coates, L, Mease, P, Gladman, D et al. (8 more authors) (2019) Long-term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study. In: 2019 ACR/ARP Annual Meeting Minutes, 08-13 Nov 2019, Atlanta, Georgia, USA.
Coates, L, Merola, J, Mease, P et al. (10 more authors) (2019) The Performance Characteristics of Composite Measures Used in a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis. In: 2019 ACR/ARP Annual Meeting, 08-13 Nov 2019, Atlanta, Georgia, USA.
Helliwell, P, Bushmakin, A, Gladman, D et al. (5 more authors) (2019) Relationships Between Minimal Disease Activity and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies. In: 2019 ACR/ARP Annual Meeting, 08-13 Nov 2019, Atlanta, Georgia, USA.
Coates, L, Bushmakin, A, FitzGerald, O et al. (5 more authors) (2019) Relationships Between Psoriatic Arthritis Disease Activity Score and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies. In: 2019 ACR/ARP Annual Meeting, 08-13 Nov 2019, Atlanta, Georgia, USA.
Deodhar, A, Helliwell, P, Boencke, W-H et al. (7 more authors) (2019) Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis Who Were Biologic-Naïve or Prior TNFα Inhibitor-Treated: Week 24 Results of a Phase 3, Randomized, Double-blind, Placebo-controlled Study. In: 2019 ACR/ARP Annual Meeting, 08-13 Nov 2019, Atlanta, GA, USA.
Ritchlin, C, Ogdie, A, Giles, J et al. (9 more authors) (2019) Impact of Baseline Body Mass Index on the Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis. In: 2019 ACR/ARP Annual Meeting, 08-13 Nov 2019, Atlanta, Georgia, USA.
Gladman, D, Coates, L, Wu, J et al. (6 more authors) (2019) Time to Response for Clinical and Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Tofacitinib, Adalimumab, or Placebo. In: 2019 ACR/ARP Annual Meeting, 08-13 Nov 2019, Atlanta, Georgia, USA.
Gladman, D, Boehncke, W-H, Gottlieb, AB et al. (7 more authors) (2019) The Effect of Guselkumab on Dactylitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis. In: Pan-American Congress of Rheumatology 2019, 27-30 Apr 2019, Quito, Ecuador.
Helliwell, P, Gottlieb, AB, Deodhar, A et al. (7 more authors) (2019) The Effect of Guselkumab on Enthesitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis. In: Pan-American Congress of Rheumatology 2019, 27-30 Apr 2019, Quito, Ecuador.
Helliwell, P, Lespessailles, E, Shuler, CL et al. (4 more authors) (2018) Ixekizumab Provides Sustained Improvement In Signs And Symptoms In Patients With Active Psoriatic Arthritis: Two Year Results From A Phase 3 Trial. In: 20th PANLAR Meeting, 07-10 Apr 2018, Buenos Aires, Argentina.
Helliwell, P, Coates, LC, FitzGerald, O et al. (8 more authors) (2018) Tofacitinib Improves Composite Endpoint Measures of Disease in Patients with Psoriatic Arthritis. In: Pan-American League of Rheumatology Associations (PANLAR) Congress 2018, 07-10 Apr 2018, Buenos Aires, Argentina.
Merashli, M, De Marco, G orcid.org/0000-0003-2406-161X, Tan, AL orcid.org/0000-0002-9158-7243 et al. (4 more authors) (2016) AB0700 Baseline Clinical Characteristics of The Leeds Sparro Early Psoriatic Arthritis Cohort: High Disease and Radiographic Involvement Are Seen Early Even in The Presence of Preserved Quality of Life. In: Annual European Congress of Rheumatology 2016, 08-11 Jun 2016, London, UK.
Proceedings Paper
Dubash, S, Alabas, O, Michelena, X et al. (9 more authors) (2020) Swollen Joints but Not Tender Joints Are Associated with Ultrasound Power Doppler Synovitis in Very Early DMARD Naive Psoriatic Arthritis. In: Arthritis and Rheumatology. ACR Convergence 2020, 05-09 Nov 2020, Online. Wiley-Blackwell .
McInnes, I, Mease, P, Hjuler, KF et al. (2 more authors) (2019) Brodalumab in psoriatic arthritis (PsA): 24-week results from the phase III AMVISON-1 and -2 trials. In: Journal of the American Academy of Dermatology. AAD 2019: American Academy of Dermatology Annual Meeting, 01-05 Mar 2019, Washington, DC, USA. Elsevier , AB28-AB28.
Helliwell, P, Deodhar, A, Gottlieb, AB et al. (7 more authors) (2019) Comparing Composite Measures of Disease Activity in Psoriatic Arthritis: Results From a Randomized Phase 2 Trial with Guselkumab. In: Annals of the Rheumatic Diseases. EULAR 2019: Annual European Congress of Rheumatology, 12-15 Jun 2019, Madrid, Spain. BMJ Publishing Group , p. 1843.
De Marco, G, Berekméri, A, Coates, LC et al. (10 more authors) (2019) Non Topical Pharmacological Treatment of Early, Untreated (DMARD-Naive, Systematic Therapy-Naive) Psoriatic Disease: a Systematic Review. In: Annals of the Rheumatic Diseases. EULAR 2019: Annual European Congress of Rheumatology, 12-15 Jun 2019, Madrid, Spain. BMJ Publishing Group , p. 904.
Gossec, L, Kirkham, B, Rahman, P et al. (4 more authors) (2018) Clinically Meaningful Improvement in Health-Related Quality of Life and the Association with Disease Activity in Psoriatic Arthritis after Treatment with Guselkumab: Results from a Randomized Placebo-Controlled Phase II Clinical Trial. In: Arthritis and Rheumatology. 2018 ACR/ARHP Annual Meeting, 19-24 Oct 2018, Chicago, IL, USA. Wiley .
Merola, JF, Coates, LC, Husni, ME et al. (3 more authors) (2018) Ixekizumab reduces disease activity up to 52 weeks in active psoriatic arthritis patients with inadequate response to tumor necrosis factor inhibitors: An assessment with the use of minimal disease activity scores. In: Journal of the American Academy of Dermatology. American Academy of Dermatology 2018 Annual Meeting, 16-20 Feb 2018, San Diego, California, USA. Elsevier , AB174-AB174.
Duarte-Garcia, A, Eder, L, Stephens-Shields, A et al. (13 more authors) (2018) Construct Validity of the Swollen and Tender Joint Counts for the Measurement of MSK Disease Activity in Psoriatic Arthritis. In: Arthritis and Rheumatology. 2018 ACR/ARHP Annual Meeting, 19-24 Oct 2018, Chicago, IL, USA. Wiley .
Gladman, DD, Boehncke, W-H, Gottlieb, AB et al. (8 more authors) (2018) The Effect of Guselkumab on Dactylitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis. In: Arthritis and Rheumatology. 2018 ACR/ARHP Annual Meeting, 19-24 Oct 2018, Chicago, IL, USA. Wiley .
Helliwell, P, Gottlieb, AB, Deodhar, AA et al. (8 more authors) (2018) The Effect of Guselkumab on Enthesitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis. In: Arthritis and Rheumatology. 2018 ACR/ARHP Annual Meeting, 19-24 Oct 2018, Chicago, IL, USA. Wiley .
Helliwell, P, Gladman, DD, Chakravarty, SD et al. (5 more authors) (2018) Efficacy of Ustekinumab on Spondylitis-Associated Endpoints in TNF-Naïve Active Psoriatic Arthritis Patients with Physician-Reported Spondylitis. In: Arthritis and Rheumatology. 2018 ACR/ARHP Annual Meeting, 19-24 Oct 2018, Chicago, IL, USA. Wiley .
Mease, PJ, Gladman, DD, van den Bosch, F et al. (10 more authors) (2018) Filgotinib, an Oral, Selective Janus Kinase 1 Inhibitor, Is Effective in Psoriatic Arthritis Patients with an Inadequate Response to Conventional Disease-Modifying Anti-Rheumatic Drugs: Results from a Randomized, Placebo-Controlled, Phase 2 Study. In: Arthritis and Rheumatology. 2018 ACR/ARHP Annual Meeting, 19-24 Oct 2018, Chicago, IL, USA. Wiley .
Gromer, D, Coates, LC, FitzGerald, O et al. (3 more authors) (2018) Identification of Treatment Naïve Patients with Psoriatic Arthritis Who Will Require a TNF Inhibitor. In: Arthritis and Rheumatology. 2018 ACR/ARHP Annual Meeting, 19-24 Oct 2018, Chicago, IL, USA. Wiley .
Genovese, M, Helliwell, P, Combe, B et al. (6 more authors) (2018) Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF inhibitors: 52-week Results from a Phase 3 Study. In: Journal of Rheumatology. 73rd Annual Meeting of The Canadian-Rheumatology-Association (CRA), 21-24 Feb 2018, Vancouver, Canada. Journal of Rheumatology Publishing Co., Ltd. , p. 996.
Helliwell, P, Lespessailles, E, Shuler, C et al. (4 more authors) (2018) Ixekizumab Provides Sustained Improvement in Signs and Symptoms in Patients with Active Psoriatic Arthritis: Two-Year Results from a Phase 3 Trial. In: Journal of Rheumatology. 73rd Annual Meeting of The Canadian-Rheumatology-Association (CRA), 21-24 Feb 2018, Vancouver, Canada. Journal of Rheumatology Publishing Co., Ltd. , pp. 998-999.
Chandran, V, Fleischmann, R, Lespessailles, E et al. (4 more authors) (2018) Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: three year results from a phase 3 study (SPIRIT-P1). In: Acta Dermato-Venereologica. 5th World Psoriasis & Psoriatic Arthritis Conference, 27-30 Jun 2018, Stockholm, Sweden. Society for Publication of Acta Dermato-Venereologica , pp. 23-24.
Merashli, M, De Marco, G, Helliwell, P et al. (6 more authors) (2016) Low Frequency of Us Determined Erosions in Early Psoriatic Arthritis: Results from The Leeds Sparro Cohort. In: Annals of the Rheumatic Diseases. EULAR 2016, 08-11 Jun 2016, London, UK. BMJ Publishing Group , p. 104.
Ndosi, ME, Hsu, MA, Cappelleri, C et al. (3 more authors) (2015) Rasch Analysis of the Psoriatic Arthritis Quality of Life and Dermatology Life Quality Index Measures in Psoriatic Arthritis. In: Journal of Investigative Dermatology. 4th World Psoriasis & Psoriatic Arthritis Conference 2015, 08-11 Jul 2015, Stockholm Waterfront Congress Center, Stockholm, Sweden. Nature Publishing Group .
Ndosi, M orcid.org/0000-0002-7764-3173, Hsu, M-A, Cappelleri, JC et al. (3 more authors) (2015) Rasch analysis of the Health Assessment Questionnaire Disability Index in psoriatic arthritis. In: Journal of Investigative Dermatology. 4th World Psoriasis & Psoriatic Arthritis Conference 2015, 08-11 Jul 2015, Stockholm, Sweden. Elsevier , S34-S34.
Ndosi, ME, Hsu, M, Cappelleri, J et al. (3 more authors) (2015) Measures of Health-Related Quality of Life in Psoriatic Arthritis: Are They Sensitive to Both Joint and Skin Aspects? [abstract]. In: Arthritis and Rheumatology. 2015 ACR/ARHP Annual Meeting, 06-11 Nov 2015, San Francisco, CA. Wiley .
Ndosi, ME, Hsu, M, Cappelleri, J et al. (3 more authors) (2015) Rasch Analysis of the Hospital Anxiety and Depression Scale in Psoriatic Arthritis: Results from the Presta Study. In: Arthritis and Rheumatology. 2015 ACR/ARHP Annual Meeting, 06-11 Nov 2015, San Francisco, CA. Wiley .